2018 ESC/ESH Guidelines for the management of arterial ...

Aboyans Victor 1- Financial Declaration

A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.

- Amgen : Hyperlipidemia (2016-2017)

- Novartis : Hypertension (2016-2017)

- Boehringer-Ingelheim : Oral anticoagulation (2016-2017)

- Bayer Healthcare : Oral anticoagulation (2016-2017)

- Pfizer/BMS alliance : Oral anticoagulation (2016-2017)

Agabiti-Rosei Enrico 1- Financial Declaration


- Doc Generici : Cardiometabolic (2016-2017)

- Bruno Farmaceutici : Cardiometabolic (2016-2017)

- Servier : Cardiovascular (2016-2017)

- Malesci : Cardiovascular (2016-2017)

- Recordati International : Cardiovascular (2016-2017)

- Guidotti : Cardiovascular (2016-2017)

- Stroder : Cardiovascular (2016-2017)

- MENARINI INTERNATIONAL : cardiovascular (2016-2017)

- Novartis : cardiovascular (2017)

Azizi Michel 1- Financial Declaration


- CVRx : Baroreceptor stimulation (2016-2017)

1/7218/02/2019

Expert Type of Relationship with Industry

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

2018 ESC/ESH Guidelines for the management of arterial hypertension - Task Force

Azizi Michel - Actelion : hypertension (2016-2017)

D - Research funding (departmental or institutional) from healthcare industry.- Quantum Genomics : Hypertension (2016)


- Recor : renal denervation (2016-2017)

Burnier Michel 1- Financial Declaration

B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.

- Boehringer- INgelheim : Diabetes (2016)

- Servier : Hypertensio (2016)

- Sankyo : Hypertension (2016)

- Menarini : Hypertension (2016-2017)

- Boehringer-Ingelheim : Diabetes (2017)

- Amgen : dialysis (2017)

- Daichi-Sankyo : Hypertension (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Bayer AG : Diabetic nephropathy (2016)

- Pfizer : Dyslipidemia (2016)

- Amgen Inc : Dyslipidemia (2016)

- Amgen Inc : Hyperparathyroidism (2016)

- Medtronic : Resistant hypertension (2016)

- Actelion : ENdothelin antagonists (2016-2017)

- Boehringer-Ingelheim : SGLT2 inhibitors (2017)

2/7218/02/2019




Clement Denis 1- Financial Declaration


- European Society of Cardiology : editor e-journal (2016-2017)

Coca Antonio 1- Financial Declaration


- Boehringer-Ingelheim : Telmisartan; Telmisartan-Amlodipine; Telmisartan-HCTZ (2016)

- Merck Serono : Bisoprolol-Amlodipine (2016-2017)

- Menarini : Nevibolol; Olmesartan; Olmesartan-Amlodipine; Olmesartan-HCTZ (2016-2017)

- Ferrer Internacional : Torasemide; CardioIncode microchips; Polypill (2016-2017)

de Simone Giovanni 1- Financial Declaration

D - Research funding (departmental or institutional) from healthcare industry.- Italian Ministry of University : Hypertension - Coronary Heart Disease (2016-2017)

Desormais Ileana

Nothing to be declared (2016-2017)

Dominiczak Anna F 1- Financial Declaration


- Servier : Cardiovascular (2016-2017)

- Menarini : Cardiovascular (2016-2017)

2- Other Positions of Influence

2.2 - Employment in healthcare industry (including part time) during the year for which you are declaring.- Non-executive Director, NHS Greater Glasgow and Clyde Health Board, this is a non-executive position with a role in a

high level strategy but not with any direct purchasing or other executive decisions. (2016-2017)

2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- Trustee of the British Heart Foundation (also a non-executive position). (2016-2017)

3/7218/02/2019




Kahan Thomas 1- Financial Declaration


- Amgen : Cardiovascular risk assessment (2016)


- Recor Medical : Renal enervation (2016)

D - Research funding (departmental or institutional) from healthcare industry.- Pfizer : Lipid lowering therapy (2016-2017)

- Medtronic : Renal denervation (2016-2017)

- Amgen Inc : Lipid lowering therapy (2017)

- Regeneration Pharmaceuticals : Lipid lowering therapy (2017)

- Recor : Renal denervation (2017)

Kerins Mary


Kjeldsen Sverre Erik 1- Financial Declaration


- Bayer : Drug producer (2016)

- Takeda Pharmaceuticals : Drug producer (2016)

- Merck Sharp & Dohme : Drug producer (2016)

- ABDiiBRAHiM : Drug producer (2016)

- Sanofi Aventis : Antihypertensive drugs (2017)

- Bayer Healthcare : Antihypertensive drugs (2017)

- Takeda Pharmaceuticals : Antihypertensive drugs (2017)

4/7218/02/2019




Kjeldsen Sverre Erik - Merck Sharp & Dohme : Antihypertensive drugs (2017)

C - Receipt of royalties for intellectual property.- Gyldendal textbook publisher : Internal medicine (2016)

D - Research funding (departmental or institutional) from healthcare industry.- Norwegian Council for Cardiovascular Diseases : Clinical reasearch (2016)

- South East Norway Health Authority : Clinical Resarch (2016)

Kreutz Reinhold 1- Financial Declaration


- Astra Zeneca : Cardiovascular (2016)

- Daiichi Sankyo : Cardiovascular, anticoagulation (2016)

- Bayer AG : Cardiovascular, anticoagulation (2016)

- Servier : Cardiovascular, hypertension (2016)

- Berlin Chemie AG : Hypertension (2016)

- Daiichi Sankyo : Anticoagulation (2017)

- Bayer AG : Anticoagulation (2017)

- Servier : Hypertension (2017)

- Berlin Menarini : Hypertension (2017)

- Astra Zeneca : Pharmacotherapy (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Bayer AG : Anticoagulation (2016-2017)


2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.- Member of the Scientific Council of the European Society of Hypertension (2016)

5/7218/02/2019




Laurent Stephane 1- Financial Declaration


- Servier : hypertension (2016-2017)


- Servier : hypertension (2016-2017)

D - Research funding (departmental or institutional) from healthcare industry.- Axelife : Cardiology (2016-2017)

Lip Gregory Y H 1- Financial Declaration


- BMS/Pfizer : Anticoagulation (2016)

- Boehringer Ingelheim : Anticoagulation (2016)

- Daiichi-Sankyo : Daiichi-Sankyo (2016)

- Medtronic : AF screening (2016-2017)

- Bayer/Janssen : Anticoagulation (2016-2017)

- Daiichi-Sankyo : Anticoagulation (2017)

- Verseon : Anticoagulation development (2017)

- Boehringer Ingelheim : Anticoagulation; Registries; Steering Committees (2017)

- Pfizer : Anticoagulation; Registries (2017)

- BMS : Antithrombotic therapy (2017)

- Novartis : Antithrombotic therapy development (2017)

D - Research funding (departmental or institutional) from healthcare industry.- BMS/Pfizer : AF Registries [unrestricted educational grant] (2016-2017)

6/7218/02/2019




Lip Gregory Y H - Daiichi-Sankyo : Systematic reviews [unrestricted educational grant] (2016-2017)


2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- I have been requested to declare that shares of ‘Gregory Lip and Associates Ltd’ are held by Prof Lip and family

members, and there are payments by Healthcare Industry to ‘Gregory Lip and Associates Ltd’ (considered a legal separate entity in UK) for services. Prof Lip has not been drawing out a director’s salary nor received any share dividends/income/personal renumeration from the company (which is a separate legal entity). (2017)

Mahfoud Felix 1- Financial Declaration


- St Jude Medical : Interventional cardiology (2016)

- Medtronic : Interventional cardiology (2016-2017)

- Recor : Interventional Cardiology (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Medtronic : Study fees (2016)

- St Jude Medical : Study fees (2016)

- Medtronic : Interventional Cardiology (2017)

- Recor : Interventional Cardiology (2017)

Mancia Giuseppe 1- Financial Declaration


- Merck Sharp & Dohme : Antihypertensie Treatment (2016-2017)

- Boehringer-Ingelheim : Antihypertensive Treatment (2016-2017)

- Daiichi Sankyo : Antihypertensive Treatment (2016-2017)

- Novartis : Antihypertensive Treatment (2016-2017)

- Menarini : Antihypertensive Treatment (2016-2017)

7/7218/02/2019




Mancia Giuseppe - Medtronic Foundation : Antihypertensive Treatment (2016-2017)

- Servier : Antihypertensive Treatment (2017)

- Recordati International : Antihypertensive Treatment (2017)


- Servier : Antihypertensie Treatment (2016)

- Sanofi Aventis : Antihypertensive Treatment (2016)

- Recordati International : Antiihypertensive Treatment (2016)


2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- Deputy Editor of the Journal of Hypertension (2017)

McManus Richard 1- Financial Declaration

D - Research funding (departmental or institutional) from healthcare industry.- OMRON Healthcare : BP monitors for research (2014&15) (2016-2017)


2.1 - Direct ownership of shares or direct financial interest in healthcare, media, education companies or in companies related to (suppliers), or in competition with the ESC and its mission: To reduce the burden of cardiovascular disease.

- Healthcare - OTHER - I hold shares in a primary care medical practice in Birmingham, UK (2016-2017)

2.2 - Employment in healthcare industry (including part time) during the year for which you are declaring.- I am a partner in a general practice in Oxford. (2016-2017)

2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- I chair the British Hypertension Society BP monitoring Working Party (2016-2017)

Narkiewicz Krzysztof 1- Financial Declaration


- Gilead : Pharmacotherapy (2016)

- Adamed : Cardiovascular pharmacotherapy (2016-2017)

8/7218/02/2019




Narkiewicz Krzysztof - Polpharma : Cardiovascular pharmacotherapy (2016-2017)

- Servier : Cardiovascular pharmacotherapy (2016-2017)

- Berlin Menarini : Cardiovascular pharmacotherapy (2016-2017)

- Krka Pharma : Cardiovascular pharmacotherapy (2016-2017)

- Gedeon Richter : Cardiovascular pharmacotherapy (2016-2017)

- Mylan : Cardiovascular pharmacotherapy (2016-2017)

- Valeant : Cardiovascular pharmacotherapy (2016-2017)

- Resmed : Respiratory medicine (2016-2017)

- Actelion : Cardiovascular pharmacotherapy (2017)

- Egis Pharma : Cardiovascular pharmacotherapy (2017)

- Sandoz : Cardiovascular pharmacotherapy (2017)

- Merck Polska : Cardiovascular pharmacotherapy (2017)

- Medtronic : Renal denervation (2017)

Redon Josep 1- Financial Declaration


- Astra Zeneca : Diabetes (2016)

- Menarini : Hypertension (2016)

- MSD : Hypertension (2016)

- Boehringer-Ingelheim : Diabetes (2016-2017)

- MENARINI INTERNATIONAL : CARDIOVASCULAR (2017)

9/7218/02/2019




Redon Josep B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.

- Daiichi Sankyo : Hypertension (2016)

Ruilope Luis Miguel 1- Financial Declaration


- Sanofi Aventis : alirocumab (2016)

- Janssen-Cilag : Canagliflozin (2016)

- Astra Zeneca : Dapagliflozin (2016)

- Novartis : Entresto and vallaran combinations (2016)

- Medtronic : European Registry of RDN (2016)

- Amgen : Evolocumab (2016)

- Menarini : olesartan and combinations (2016)

- Daiichi Sankyo : Olmesartan & combinations (2016)

- Merck Sharp & Dohme : Olmesartan and combinations (2016)

- Servier : perindopril new combinations (2016)

- Bayer AG : Finerenone (2016-2017)

- Vifor International : patiromer (2016-2017)

- Daiichi Sankyo : Arterial Hypertension (2017)

- Medtronic : Renal denervation (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Astra Zeneca : diabetes, nocturnal BP and dapagliflozina (2016)

10/7218/02/2019




Ruschitzka Frank 1- Financial Declaration


- Novartis : Drug (2016)

- St. Jude Medical : Medical devices (2016)

- Heartware : Ventricular assist devices (2016)

- Amgen : Drug (2016-2017)

- Pfizer : Drug (2016-2017)

- BMS : Drug (2016-2017)

- Servier : Drugs (2016-2017)

- Sanofi Aventis : Drugs (2016-2017)

- Zoll Medical : LifeVest (2016-2017)

- Fresenius Nutrition : Steering Committee Meetings of Clinical Trials (2016-2017)

- Vifor International : Steering Committee Meetings of Clinical Trials (2016-2017)

- Cardiorentis : TRUE-AHF Steering Committee (2016-2017)

- Bayer Healthcare : Drug (2017)

- Astra Zeneca : Drugs (2017)

- Novartis : Drugs (2017)

- Roche Pharma : Drugs (2017)

- Abbott : Medical Devices (2017)

- Boehringer-Ingelheim : Satellite Symposium (2017)

- Heartware : Ventricular assist device (2017)

11/7218/02/2019




Ruschitzka Frank B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.

- Bayer : Postgraduate Heart Failure Course (Grant to Zurich Heart House) (2016)

- St Jude Medical : Postgraduate Heart Failure Course (Grant to Zurich Heart House) (2016)

- Novartis : Postgraduate Heart Failure Course (Grant to Zurich Heart House) (2016-2017)

- Bayer Healthcare : Postgraduate Heart Failure Course (Grant to Zurich Heart House) (2017)

- St. Jude Medical : Postgraduate Heart Failure Course (Grant to Zurich Heart House) (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Mars : Flavanol-like cocoa products (2016-2017)

- St. Jude Medical : Medical Devices (2017)

- Novartis : VASCEND (2017)


2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- Cardiomaxx Consulting GmbH account for managing reimbursements and expenses (2016-2017)

Schmieder Roland 1- Financial Declaration


- Boehringer-Ingelheim : Nephrology and Hypertension (2016)

- Kona Medical : Nephrology and Hypertension (2016)

- Medtronic : Nephrology and Hypertension (2016-2017)

- Novartis : Nephrology and Hypertension (2016-2017)

- Servier : Nephrology and Hypertension (2016-2017)

- Berlin Chemie AG : Nephrology and Hypertension (2016-2017)

- Recor : Nephrology and Hypertension (2016-2017)

12/7218/02/2019




Schmieder Roland - Bayer Vital : Nephrology and Hypertension (2016-2017)

- Astra Zeneca : Nephrology and Hypertension (2017)

- Daiichi Sankyo : Nephrology and Hypertension (2017)

- Novo-Nordisk : Nephrology and Hypertension (2017)

- Rox Medical : Nephrology and Hypertension (2017)

- Vasopharm : Nephrology and Hypertension (2017)

- Ablative Solution : Nephrology and Hypertension (2017)

- Hexal : Nephrology and Hypertension (2017)

- Boehringer-Ingelheim : Nephrology and Hypertension, Diabetes mellitus (2017)

D - Research funding (departmental or institutional) from healthcare industry.- BMBF - German Ministry of Research and Education : Nephrology and Hypertension (2016)

- Rox Medical : Nephrology and Hypertension (2016)

- Recordati International : Nephrology and Hypertension (2016)

- Kona : Nephrology and Hypertension (2016)

- Vascular Dynamics : Nephrology and Hypertension (2016)

- Vasopharm : Nephrology and Hypertension (2016)

- Ablative Solution : Nephrology and Hypertension (2016)

- Medtronic : Nephrology and Hypertension (2016-2017)

- Novartis : Nephrology and Hypertension (2016-2017)

- Recor : Nephrology and Hypertension (2016-2017)

- Boehringer Ingelheim : Nephrology and Hypertension (2016-2017)

13/7218/02/2019




Schmieder Roland - Ablative Solutions : Nephrology and Hypertension (2017)

- Roxmedical : Nephrology and Hypertension (2017)

Shlyakhto Evgeny 1- Financial Declaration


- Krka Pharma : Arterial Hypertension (2016-2017)

- Novartis : Arterial Hypertension, Heart Failure (2016-2017)

- Merck Sharp & Dohme : Atherosclerosis (2016-2017)

- Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation (2016-2017)

- Pfizer : General Cardiology (2016-2017)

Spiering Wilko 1- Financial Declaration


- Janssen-Cilag. : Canagliflozin. (2016)

- Vascular Dynamics. : Endovascular baroreflex amplification device. (2016)

- Vascular Dynamics : Endovascular barreflex amplification device. (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Vascular Dynamics. : Endovascular baroreflex amplification device. (2016)

- Vascular Dynamics : Endovascular barreflex amplification device. (2017)


2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- President Dutch Hypertension Society. (2016-2017)

14/7218/02/2019




Tsioufis Costas 1- Financial Declaration


- Astra Zeneca : Cardiology (2016-2017)

- Bayer : Cardiology (2016-2017)

- Boehringer-Ingelheim : Cardiology (2016-2017)

- Medtronic : Cardiology (2016-2017)

- Novartis : Cardiology (2016-2017)

- Pfizer : Cardiology (2016-2017)

- Servier : Cardiology (2016-2017)

- St Jude Medical : Cardiology (2016-2017)

- Sanofi Aventis : Cardiology (2016-2017)

- Chiesi Pharma : Cardiology (2016-2017)

- Recordati International : Cardiology (2016-2017)

- Vianex : Cardiology (2016-2017)

- Winmedica : Cardiology (2016-2017)

- ELPEN : Cardiology (2016-2017)

E - Research funding (personal).- Medtronic : Cardiology (2016-2017)

- St Jude Medical : Cardiology (2016-2017)

Williams Bryan 1- Financial Declaration


- Boehringer-Ingelheim : Hypertension (2016-2017)

15/7218/02/2019




Williams Bryan - Daiichi Sankyo : Hypertension (2016-2017)


- Servier : Hypertension (2016-2017)

- Vascular Dynamics Inc, USA : Hypertension - device based therapyy (2016-2017)

- Pfizer : Hypertension and cardiovascular risk management (2016-2017)


2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.- Trustee of BP UK - a patient's association (2016-2017)

Zanchetti Alberto

Declaration not submitted (2017)

1- Financial Declaration


- Menarini : Speaker Fees (2016)

- Recordati International : Speaker Fees (2016)

16/7218/02/2019




Agewall Stefan 1- Financial Declaration


- Astra Zeneca : Antiplatelet treatment (2017)

Aksnes Tonje 1- Financial Declaration


- Astra Zeneca : Honoraria for lecture (2017)

Andersen Karl 1- Financial Declaration


- Novartis : ACS (2017)

Aydogdu Sinan 1- Financial Declaration


- Amgen : Antihyperlipidemics (2017)

- Astra Zeneca : Antiplatelets (2017)

- Daiichi Sankyo : Antiplatelets (2017)

- Bayer : Oral anticoagulant agents (2017)

- Boehringer-Ingelheim : oral anticoagulants (2017)

- Pfizer : oral anticoagulants (2017)

Bajraktari Gani

Nothing to be declared (2017)

24/08/2018

2018 ESC/ESH Guidelines for the management of arterial hypertension - Reviewers



17/72

Baranova Elena 1- Financial Declaration


- Abbott : Aspirin (2017)

- Bayer : aspirin (2017)

- Boehringer-Ingelheim : Dabigatrane etexilate, empagliflozine (2017)

- Berlin Menarini : Ranolazine, Zophenopril, Lercanidipine (2017)

- Servier : Triplixam, Preterax, Noliprel (2017)


- Novartis : ARNI (2017)

- Sanofi Aventis : PCSK-9 (2017)

Barbato Emanuele 1- Financial Declaration


- Boston Scientific : Education courses on rotational atherectomy (2017)

- Abbott Vascular : Educational courses on FFR (2017)

D - Research funding (departmental or institutional) from healthcare industry.- St Jude Medical : Unrestricted grant for an investigator-driven study (2017)

Benkhedda Salim 1- Financial Declaration


- Novartis : Report HF study (2017)

Bertomeu Martinez Vicente 1- Financial Declaration


- Daiichi Sankyo : Anticoagulation (2017)

24/08/2018




18/72

Bertomeu Martinez Vicente - Pfizer : Anticoagulation (2017)

- Menarini : Coronary Desease (2017)

Bochud Murielle


Borghi Claudio 1- Financial Declaration


- Novartis : Heart Failure (2017)

- Servier : Hypertension, dislipydemia, heart failure (2017)

- Menarini : Hyperuricemia and Gout (2017)

- Grunenthal : Hyperuricemia and Gout (2017)

Boutouyrie Pierre 1- Financial Declaration


- ACER Therapeutics : celiprolol (2017)

Brady Adrian Jb 1- Financial Declaration


- Daiichi Sankyo : AF anticoagulation (2017)

- Bayer AG : anticoagulation (2017)

- Astra Zeneca : Antiplatelet therapy (2017)

- Sanofi Aventis : Lipid lowering (2017)

- Amgen Inc : Lipid lowering (2017)

- MSD : Lipid lowering (2017)

24/08/2018




19/72

Brguljan Jana


Bueno Hector 1- Financial Declaration


- Pfizer : Apixaban (2017)

- Bristol Myers Squibb : Apixaban (2017)

- Bayer : Aspirin, rivaroxaban (2017)

- MEDSCAPE-the heart.og : Inespecific (2017)

- Sanofi Aventis : PCSK9 inhibitors (2017)

- Novartis : Serelaxin, ACZ885, AHF Academy, (2017)

- Astra Zeneca : Ticagrelor (2017)

- Ferrer Internacional : Trinomia (polypill) (2017)



E - Research funding (personal).- BMS : CV013-011 - STANDUP-AHF trial (2017)

- Novartis : LCZ696 - PROMISE trial / PERSPECTIVE trial / PREFER Study (2017)

- Janssen-Cilag : Rivaroxaban - GEMINI ACS Trials 1 & 2 (2017)

- Astra Zeneca : Ticagrelor - EPICOR Study, THEMIS trial (2017)


2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.- VP elect. Spanish Society of Cardiology FAHA (2017)

24/08/2018




20/72

Burkard Thilo 1- Financial Declaration


- Boehringer-Ingelheim : Diabetes mellitus (2017)

- Sanofi Aventis : Dyslipidemia (2017)

- Servier : Hypertension, Dyslipidemia (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Novartis : Study site of a Novartis - initiated hypertension trial (2017)

Caiani Enrico Gianluca 1- Financial Declaration


- Medtronic : implanted defibrillators (2017)

Caraus Alexandru 2- Other Positions of Influence

2.2 - Employment in healthcare industry (including part time) during the year for which you are declaring.- Deputy Director Institute of Cardiology (2017)

Carlberg Bo


Carvalho Rodrigues Manuel


Cassar Demarco Daniela


Chapman Neil


Chazova Irina


24/08/2018




21/72

Cifkova Renata


Cleland John 1- Financial Declaration


- Philips : Cardiac Imaging (2017)

- Amgen : Heart Failure (2017)

- Medtronic : Heart Failure (2017)


- Servier : Heart Failure (2017)

- Johnson & Johnson : Heart Failure (2017)

- Bayer Healthcare : Heart Failure (2017)

- Vifor International : Heart Failure (2017)

- Roche Diagnostics : Heart Failure (2017)

- Zoll Medical : Heart Failure (2017)

- Sensible Medical : Heart Failure (2017)

- Stealthpeptides : Heart Failure (2017)

- Corvedia : Heart Failure (2017)

- Actelion : Pulmonary Hypertension (2017)


- Bayer Healthcare : CV Disease (2017)


24/08/2018




22/72

Cleland John - Novartis : Heart failure (2017)

- Philips : Heart Failure (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Bayer Healthcare : CV Disease (2017)



- Philips : Heart Failure (2017)

- Alere : Heart failure (2017)

- Roche Diagnostics : Heart Failure (2017)

- Thermofisher : Heart Failure (2017)

- Stealth Biopharmaceuticals : heart failure (2017)



- Merck Serono : Bisoprolol-Amlodipine (2017)

- Menarini : Nevibolol; Olmesartan; Olmesartan-Amlodipine; Olmesartan-HCTZ (2017)

- Ferrer Internacional : Torasemide; CardioIncode microchips; Polypill (2017)

Collet Jean-Philippe 1- Financial Declaration


- Bristol Myers Squibb : Lecture fees representing 2000 euros for 2017. (2017)

- Roche Diagnostics : Lecture fees representing 800 euros for 2017. (2017)

- Bayer Healthcare : Speaker Fees for antiplatelet therapy. This represented 2000 euros in total for 2017. (2017)

- Servier : SPEAKER FEES OF 1000 EUROS IN 2017 (2017)

24/08/2018




23/72

Collet Jean-Philippe D - Research funding (departmental or institutional) from healthcare industry.- Boston Scientific : ACADEMIC RESEARCH DONATION TO THE ACTION FOUNDATION (www.action-fonds.org) (2017)

- Bayer AG : ACADEMIC RESEARCH FUNDINGS (ADRIFT TRIALS) to the action study group (www.action-fonds.org) (2017)

- Astra Zeneca : ACADEMIC RESEARCH FUNDINGS (ALPHEUS TRIAL) to the action study group (www.action-fonds.org) (2017)

- Medtronic : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017)

- Bristol Myers Squibb and Pfizer : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017)

De Backer Guy 1- Financial Declaration


- Abbott : speaker fee, 2017 (2017)

de Backer Tine Leonie Marie



- Pfizer : anticoagulation, hypertension (2017)


- Daiichi Sankyo : Hypertension, anticoagulation (2017)

De Leeuw Peter W


De Pauw Michel 1- Financial Declaration



- Actelion : Pulmonary Hypertension (2017)

24/08/2018




24/72

Delgado Victoria 1- Financial Declaration


- Abbott Vascular : Mitraclip (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Boston Scientific : pacemakers (2017)

- Medtronic : pacemakers (2017)

- Biotronik : pacemakers (2017)

- Edwards Lifesciences : valves (2017)

Dendale Paul 1- Financial Declaration


- Amgen : lipids (2017)


- Abbott : CV (2017)

- Astra Zeneca : cv drugs (2017)

- Bayer : cv medication (2017)

- Boehringer-Ingelheim : cv medication (2017)

- Daiichi Sankyo : cv medication (2017)

- Novartis : cv medication (2017)

- Vifor International : cv medication (2017)

- Therabel : cv medication (2017)

- Philips : echocardio (2017)

- GE Healthcare : echocardio (2017)

24/08/2018




25/72

Dendale Paul - Medtronic : pm (2017)

- St Jude Medical : pm (2017)

- Biotronik : pm (2017)

- Boston Scientific : stents (2017)

Denolle Thierry 1- Financial Declaration


- Novartis : cardiology (2017)

- Servier : cardiology (2017)


2.2 - Employment in healthcare industry (including part time) during the year for which you are declaring.- Biotrial CRO, Rennes, France (part time for consultancy) (2017)

Diener Hans-Christoph 1- Financial Declaration


- Portola Pharmaceuticals : Andexanet alfa (2017)

- Allergan : Spasticity (2017)

- Abbott : Stroke (2017)

- Astra Zeneca : Stroke (2017)

- Boehringer-Ingelheim : Stroke (2017)

- Covidien : Stroke (2017)

- Daiichi Sankyo : Stroke (2017)

- Medtronic : Stroke (2017)

- Novartis : Stroke (2017)

24/08/2018




26/72

Diener Hans-Christoph - Pfizer : Stroke (2017)

- Servier : Stroke (2017)

- Sanofi Aventis : Stroke (2017)

- GlaxoSmithKline : Stroke (2017)

- Bayer Healthcare : Stroke (2017)

- Merck Sharp & Dohme : Stroke (2017)

- Ev3 : Stroke (2017)

- CoAxia : Stroke (2017)

- D-Pharm : Stroke (2017)

- Neurobiological technologies : Stroke (2017)

- Paion : Stroke (2017)

- Thrombogenics : Stroke (2017)

- Bristol Myers Squibb : Stroke Prevention (2017)

- St. Jude : Stroke, LAA occlusion (2017)

D - Research funding (departmental or institutional) from healthcare industry.- German Stroke Foundation : Stroke (2017)

- German Research Foundation : Stroke (2017)

- German Ministry of Education and Research (BMBF) : Stroke (2017)

- Hein-Nixdorf Foundation : Stroke (2017)

- NIH : Stroke (2017)

24/08/2018




27/72

Dizdarevic-Hudic Larisa 1- Financial Declaration


- Pfizer : Ertugliflozin (subinvestigator in study) (2017)

Djordjevic-Dikic Ana


Dorobantu Maria


Erdine Serap


Fagard Robert


Farsang Csaba


Ferrini Marc 1- Financial Declaration


- Bristol Myers Squibb : Apixaban (2017)

- Novartis : LCZ (2017)

- Bayer : Rivaroxaban, Aspirin (2017)


Fitzsimons Donna


24/08/2018




28/72

Foscoli Marina


Fras Zlatko 1- Financial Declaration


- Pfizer : anticoagulation therapy (2017)

- Astra Zeneca : antiplatelet therapy (2017)

- Boehringer-Ingelheim : cardiodiabetology (2017)

- Amgen : lipid treatment (2017)

- Sanofi Aventis : lipid treatment (2017)

- Krka Pharma : lipids (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Sanofi Aventis : lipidology (2017)

E - Research funding (personal).- Sanofi Aventis : lipidology (2017)

Gaemperli Oliver 1- Financial Declaration


- GE Healthcare : Imaging (2017)

Gerdts Eva 1- Financial Declaration



24/08/2018




29/72

Gottsater Anders 1- Financial Declaration


- Gore : Endovascular stents (2017)

- Pfizer : Low molecular weight heparin, NOAC (2017)

- Bayer : NOAC (2017)

- Amgen : PCSK-9 inhibition (2017)

Graham Ian Maklim 1- Financial Declaration


- Amgen : Advisory Board attendance (2017)

- Menarini : Lectures on Prevention and lipid Guidelines only (2017)

- Merck Sharp & Dohme : Lestures on Prevention and Pipid Guidelines only (2017)

Grassi Guido 1- Financial Declaration



- Medtronic : Cardiovascular (2017)

- Menarini : Cardiovascular (2017)

- Merck Sharp & Dohme : Cardiovascular (2017)

Halimi Jean-Michel 1- Financial Declaration


- Ablynx : caplacizumab (2017)

- Alexion : eculizumab (2017)

24/08/2018




30/72

Halimi Jean-Michel - Servier : hypertension (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Novartis : Tuberous Sclerosis Complex (2017)

Haller Hermann 1- Financial Declaration


- Astra Zeneca : Kidney (2017)

- Boehringer-Ingelheim : Kidney (2017)

- Vifor International : Kidney (2017)

- Bayer AG : Kidney (2017)

- Fresenius Medical Care : Kidney (2017)

- Alexion Pharma : Kidney (2017)

- MedWiss GmbH : Kidney (2017)

- Phenos GmbH : Kidney (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Astra Zeneca : Kidney (2017)

- Boehringer-Ingelheim : Kidney (2017)

- Vifor Pharma : Kidney (2017)

Heagerty Anthony 1- Financial Declaration


- Daiichi Sankyo : Hypertension (2017)

24/08/2018




31/72

Hindricks Gerhard 1- Financial Declaration


- Abbott : Pacemaker, Ablation (2017)

- Biosense Webster : Pacemaker, Ablation (2017)

- Biotronik : Pacemaker, catheter (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Abbott, Biotronik, Medtronic, Boston Scientific : Electropyhsiology, arrhythmias (2017)


2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- The Heart Center Leipzig / University Hospital for Cardiology, Cardiac Surgery and Pediatric Cardiology is part of the

Helios Hospital Group. (2017)

Hobbs Richard 1- Financial Declaration


- Bayer : AF (2017)

- Boehringer-Ingelheim : AF, diabetes (2017)

- Amgen : Lipids/Anticoag (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Pfizer : ;lipids (2017)

Iung Bernard 1- Financial Declaration


- Boehringer Ingelheim : Anticoagulants (2017)

- Novartis : Heart failure drugs (2017)

- Edwards Lifesciences : Heart valve prostheses (2017)

24/08/2018




32/72

Jankowski Piotr 1- Financial Declaration


- Pfizer : Atrial fibrillation (2017)

- Astrazeneca : CAD (2017)

- Amgen : Hypercholesterolemia (2017)

- SanofiAventis : Hypercholesterolemia (2017)


E - Research funding (personal).- SanofiAventis : Hypercholesterolemia (2017)

Jelakovic Bojan


Jennings Catriona Sian


Juni Peter 1- Financial Declaration

D - Research funding (departmental or institutional) from healthcare industry.- Astra Zeneca : Anti-platelet Therapy (2017)

- Biotronik : Drug-eluting stents (2017)

- Biosensors International Group : Drug-eluting stents (2017)

- The Medicines Company : Thrombin inhibitors (2017)


2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- Peter Jüni has received research grants to the institution from Astra Zeneca, Biotronik, Biosensors International, Eli Lilly

and The Medicines Company, and serves as unpaid member of the steering group of trials funded by Astra Zeneca, Biotronik, Biosensors, St. Jude Medical and The Medicines Company. (2017)

24/08/2018




33/72

Karpettas Nikos 1- Financial Declaration


- Sanofi Aventis : Irbesartan - Hypertension (2017)

Katus Hugo 1- Financial Declaration


- Daiichi Sankyo : Lixiana_NOAK (2017)


- Bayer Vital : Xarelto-NOAK (2017)

D - Research funding (departmental or institutional) from healthcare industry.- St Jude Medical : Biobank (2017)

- Philips : MRT (2017)

Knuuti Juhani 1- Financial Declaration


- Astra Zeneca : Consultancy for a research project for ischemic heart disease (2017)

- GE Healthcare : Consultancy for myocardial perfusion imaging agent (2017)

Kraemer Bernhard 1- Financial Declaration



- Pfizer : NOAC (2017)

- Boehringer-Ingelheim : SGLT-2 inhibitor (2017)

- Chiesi Pharma : Transplantation (2017)

24/08/2018




34/72

Kraemer Bernhard 2- Other Positions of Influence

2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- President of the German Hypertension Society DHL (2017)

Kroon Abraham 1- Financial Declaration


- CVRx : hypertension, baroreflex activation therapy in resistant hypertension (2017)

- Vascular Dynamics : hypertension, MobiusHD carotid stent in resistent hypertension (2017)

- Recor Medical : hypertension, renal denervation in resistent hypertension (2017)

Lancellotti Patrizio 1- Financial Declaration


- Servier : Ischemic Heart Disease (2017)



Lazareva Irina 1- Financial Declaration


- Actelion, : macitentan, selecsipag (2017)

Leclercq Christophe 1- Financial Declaration


- Abbott : devices (2017)

- Boston Scientific : devices (2017)

- Medtronic : devices (2017)

- Biotronik : devices (2017)

24/08/2018




35/72

Leclercq Christophe - LIvanova : devices (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Biotronik : devices (2017)

Linhart Ales 1- Financial Declaration


- Servier : Arterial hypertension, coronary heart disease, heart failure (2017)

- Boehringer-Ingelheim : Aterial fibrillation, diabetes (2017)

- Sanofi Aventis : Fabry disease (2017)

- Shire HGT : Fabry disease (2017)

- Novartis : Heart failure (2017)

Lovic Dragan


Lurbe Empar


Manolis Athanasios John 1- Financial Declaration


- Bayer AG : atrial fibrillation (2017)

- Servier : hypertension (2017)

- Berlin Chemie AG : hypertension (2017)

- Ferrer Internacional : hypertension (2017)

- Recordati International : hypertension (2017)

- Menarini : hypertension, heart failure (2017)

24/08/2018




36/72

Manolis Athanasios John D - Research funding (departmental or institutional) from healthcare industry.- Bayer : AF (2017)

- Boehringer-Ingelheim : AF (2017)

- Amgen : hyperlipidemia (2017)

- Sanofi Aventis : hyperlipidemia (2017)

McDonagh Theresa 1- Financial Declaration


- Vifor International : Ferrinject (2017)

- Novartis : Honoraria (2017)

- Bayer AG : Honoraria (2017)

Mercuro Giuseppe 1- Financial Declaration

D - Research funding (departmental or institutional) from healthcare industry.- Novartis : Biological treatment in coronary artery disease (2017)



- Education (2017)

Messerli Franz 1- Financial Declaration


- Medscape : Cardiology (2017)

- American College of Cardiology : Cardiology (2017)

- Pfizer : Hypertension (2017)


24/08/2018




37/72

Messerli Franz - Menarini : Hypertension (2017)

- Sandoz : Hypertension (2017)

- Hikma : Hypertension (2017)

- Medtronics : Hypertension (2017)

Metsarinne Kaj 1- Financial Declaration

D - Research funding (departmental or institutional) from healthcare industry.- Novo-Nordisk : semaglutide (2017)

Miglinas Marius 1- Financial Declaration



- Krka Pharma : hypertension (2017)

Muiesan Maria Lorenza 1- Financial Declaration

D - Research funding (departmental or institutional) from healthcare industry.- Novartis : sacubritil/valsartan (2017)

Najafov Ruslan


Nixdorff Uwe


Noppe Stephanie 1- Financial Declaration

D - Research funding (departmental or institutional) from healthcare industry.- LIH(luxembourg institute of health) : Etude ORISCAV (responsable: alaa alkerwi) (2017)

24/08/2018




38/72

Olsen Michael Hecht 1- Financial Declaration


- Astra Zeneca : Management of Hypertension (2017)

- Servier : Management of Hypertension (2017)

- Boehringer-Ingelheim : SGLT2 inhibitors (2017)

E - Research funding (personal).- Novo Nordisk Foundation : Research Stipendium (2017)


2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- I own a small percentage of ATAH which is a small, new start up IT Company producing decision support for Health Care

(Cardio.Care). (2017)

Pagava Zurab 1- Financial Declaration


- Berlin Chemie AG (Georgia) : Spieker fees (2017)

- Servier (Georgia) : Spieker fees (2017)

- AstraZeneca (Georgia) : Spieker fees (2017)

Pall Denes 1- Financial Declaration


- Novartis : cardiovascular / hypertension (2017)

- Teva Pharmaceutical Industries : cardiovascular / hypertension (2017)

- Berlin Chemie AG : nebivolol / cardiovascular, hypertension (2017)

- Egis Pharma : perindopril, indapamid / cardiovascular, hypertension (2017)

- Krka Pharma : valsartan, telmisartan / cardiovascular, hypertension (2017)

24/08/2018




39/72

Pall Denes B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.

- Daiichi Sankyo : atrial fibrillation (2017)

- Pfizer : diabetes (2017)

- Astra Zeneca : diabetes / hypertriglyceridaemia (2017)

- Boehringer-Ingelheim : diabetes, heart failure (2017)

- Bayer : NOAC / cardiovascular (2017)

Parati Gianfranco 1- Financial Declaration


- OMRON Healthcare : Honoraria for lectures on Blood Pressure Measurement (2017)

- Daiichi Sankyo : Honoraria for lectures on Hypertension (2017)

- Pfizer : Honoraria for lectures on Hypertension (2017)

- Menarini : Honoraria for lectures on Hypertension (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Daiichi Sankyo : research on hypertension (2017)

- Pfizer : research on hypertension (2017)

- Menarini : research on hypertension (2017)

Pavlova Olga


Pechere-Bertschi Antoinette 1- Financial Declaration


- Servier : cardiovascular (2017)

- Menarini : cardiovascular (2017)

24/08/2018




40/72

Pechere-Bertschi Antoinette B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.

- Boehringer-Ingelheim : nephrology (2017)

Perk Joep


Piepoli Massimo Francesco


Polonia Jorge Manuel 1- Financial Declaration


- Speaker: Astra Zeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Jaba Recordati, Medinfar, Menarini, Novartis, Sanofi-Aventis,Servier : Antihypertensive drugs and antidiabetic drugs several (2017)

- Tecnimede : antiihypertensiove drugs (2017)

Ponikowski Piotr 1- Financial Declaration


- Boehringer-Ingelheim : anticoagulant, diabetes (2017)

- Respicardia : devices (2017)

- Novartis : heart failure (2017)

- Cardiorentis : heart failure (2017)

- Berlin Chemie AG : heart failure (2017)

- Bayer Healthcare : heart failure (2017)

- Vifor Pharma ltd : heart failure (2017)

- CIBIEM : heart failure (2017)

- Servier : heart failure, coronary artery disease (2017)

24/08/2018




41/72

Ponikowski Piotr - Amgen : heart failure, lipids (2017)

- Pfizer : lipids, heart failure (2017)


- Respicardia : anticoagulant (2017)

- BioControl : devices (2017)

- Cardionomic : devices (2017)

- Impuls Dynamics : devices (2017)


- Bayer Healthcare : heart failure (2017)

- CIBIEM : heart failure (2017)

- National Institute of Health : heart failure (2017)

- Servier : heart failure, coronary artery disease (2017)

- Amgen : heart failure, lipids (2017)

- European Union grant : heart failure, prevention (2017)

Porsti Ilkka 1- Financial Declaration


- Astra Zeneca : Hyperkalemia (2017)



- Healthcare - OTHER - Small amount of shares in Orion Pharma Ltd (2017)

24/08/2018




42/72

Raev Dimitar 1- Financial Declaration


- Daiichi Sankyo : AF (2017)

- Johnson & Johnson : CAD (2017)

- Astra Zeneca : CAD, HF (2017)

- Pfizer : HF (2017)

- Novartis : HF, ACS (2017)

Richter Dimitrios 1- Financial Declaration


- Edwards Lifesciences : aortic stenosis (2017)

- Menarini : CAD- hypertension (2017)

- Novo-Nordisk : diabetes (2017)

- Novartis : hypertension (2017)

- Unipharma : hypertension-thrombosis (2017)

- Abbott : lipids (2017)

- Amgen : lipids (2017)

- Sanofi Aventis : Lipids (2017)

- Lilly : Lipids (2017)

- Unilever : lipids (2017)

- Merck Sharp & Dohme : lipids (2017)

- Vianex : lipids (2017)

24/08/2018




43/72

Richter Dimitrios - Galenica : Lipids (2017)

- Teva Pharmaceutical Industries : lipids, hypertension (2017)

- Bayer Healthcare : Thrombosis (2017)

Rimoldi Stefano Flavio 1- Financial Declaration


- Servier : Cardiology (2017)

- Menarini : Cardiology (2017)

Roffi Marco 1- Financial Declaration

D - Research funding (departmental or institutional) from healthcare industry.- Boston Scientific : Stents (2017)

- Medtronic : Stents (2017)

- Biotronik : stents (2017)

- Terumo Inc : stents (2017)

- Abbott Vascular : stents (2017)

Romanova Tatiana


Saade Georges 1- Financial Declaration


- Servier : HONORARIA (2017)

- Bayer : speaker fees (2017)

- Boehringer-Ingelheim : speaker fees (2017)

- Novartis : speaker fees (2017)

24/08/2018




44/72

Saade Georges - Pfizer : speaker fees (2017)


- Vifor International : investigator (2017)


2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.- American College of Cardiology (2017)

Sakalyte Gintare 1- Financial Declaration


- Sanofi Aventis : Investigator fee in the clinical trial (2017)

D - Research funding (departmental or institutional) from healthcare industry.- European Research Foundation FP7 : Diagnostic Imaging Strategies for Patients with Stable Chest Pain and

Intermediate Risk of Coronary Artery Diasease: Comparative Effectiveness Research of Existing Technologies (2017)


2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.- Lithuanian Health Ministry (2017)

Sattar Naveed 1- Financial Declaration


- Astra Zeneca : GLP-1 receptor agonist (2017)

- Novo-Nordisk : GLP-1 receptor agonist (2017)

- Amgen : PCSK9 (2017)

- Sanofi Aventis : PCSK9 (2017)

- Boehringer-Ingelheim : SGLT2 inhibitor (2017)

- Eli Lilly : SGLT2 inhibitor (2017)

24/08/2018




45/72

Sattar Naveed - Janssen-Cilag : SGLT2 inhibitor (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Boehringer-Ingelheim : SGLT2 inhibitor (2017)

Schunkert Heribert 1- Financial Declaration


- Amgen : N/A (2017)

- Astra Zeneca : N/A (2017)

- Boehringer-Ingelheim : N/A (2017)

- Daiichi Sankyo : N/A (2017)

- Novartis : N/A (2017)

- Pfizer : N/A (2017)

- Servier : N/A (2017)

- Sanofi Aventis : N/A (2017)

- St. Jude : N/A (2017)

- MSD SHARP & DOHME : N/A (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Astra Zeneca : N/A (2017)

Sdiri Wissem


Seferovic Petar 1- Financial Declaration


- Servier : coronary disease, heart failure (2017)

24/08/2018




46/72

Seferovic Petar - Boehringer-Ingelheim : heart failure, hypertension (2017)

- Pfizer : heart failure, hypertension (2017)

- Berlin Chemie AG : heart failure, hypertension (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Ministry of Science and Education of the Republic of Serbia : heart failure, myocardial and pericardial disease (2017)

Segura Julian 1- Financial Declaration



- Medtronic : Cardiovascular (2017)

- Pfizer : Cardiovascular (2017)

- Menarini : Cardiovascular (2017)

Shaker Amin Fouad 1- Financial Declaration


- Astra Zeneca : Brillique Crestor (2017)

- Merck Sharp & Dohme : Ingy (2017)

- Pfizer : Lipitor Norvasc (2017)

Shechter Michael 1- Financial Declaration


- Itamar Medical, Inc. Cesarea, Israel : EndoPat - endothelial function (2017)



- Krka Pharma : Arterial Hypertension (2017)

24/08/2018




47/72

Shlyakhto Evgeny - Novartis : Arterial Hypertension, Heart Failure (2017)

- Merck Sharp & Dohme : Atherosclerosis (2017)

- Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation (2017)

- Pfizer : General Cardiology (2017)

Simpson Iain A 2- Other Positions of Influence

2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- Member and Past President of the British Cardiovascular Society Member of the Management Board of the American

College of Cardiology National Cardiovascular Data Registries (2017)

Siostrzonek Peter 1- Financial Declaration


- Astra Zeneca : ACS (2017)

- Lilly : ACS (2017)

- Boehringer-Ingelheim : Anticoagulation (2017)


- Sanofi Aventis : Lipid (2017)

- Amgen : Lipid therapy (2017)

- Servier : SCA (2017)


- Boehringer-Ingelheim : Diabetes, anticoagulation (2017)


24/08/2018




48/72

Sirenko Yuriy 1- Financial Declaration


- Takeda Pharmaceuticals : Asilsartan (2017)

- Pfizer : Atorvastatin (2017)

- Sanofi Aventis : Ramipril (2017)

- Bayer AG : Riociguat (2017)

- Servier : Triplexam (2017)

Slavomira Filipova 1- Financial Declaration


- Servier : investigator of multicentric international trial (2017)

C - Receipt of royalties for intellectual property.- Servier : investigator of multicentric international trial (2017)

Sokolovic Sekib


Sousa Uva Miguel


Stanton Alice


Stergiou Georgios 1- Financial Declaration


- Boehringer-Ingelheim : Anticoagulant therapy (2017)

- OMRON Healthcare : blood pressure monitors (2017)

24/08/2018




49/72

Stergiou Georgios - Maisense : Blood pressure monitors (2017)

- Microlife : blood pressure monitors (2017)

- Novartis : hypertension (2017)


- Sanofi Aventis : hypertension (2017)

- Menarini : hypertension (2017)

- Vianex : hypertension (2017)

- Pharmathen : hypertension (2017)

- Galenica. : hypertension (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Microlife : Hypertension (2017)

- InBody : Hypertension (2017)

- iHealth : Hypertension (2017)

- Maisanse : Hypertension (2017)

Thomopoulos Costas 1- Financial Declaration



- St Jude Medical : Hypertension (2017)

- Sanofi Aventis : Hypertension (2017)


- MSD : Lipids (2017)

24/08/2018




50/72

Thomopoulos Costas E - Research funding (personal).- Hellenic Society of Hypertension : Protocol grant (2017)

Trusinskis Karlis 1- Financial Declaration


- Pfizer : atorvastatin, apixaban (2017)

- Boehringer-Ingelheim : dabigatran, empagliflozin (2017)

- Servier : ivabradine, perindopril (2017)

- Novo-Nordisk : liraglutide (2017)

- Berlin Menarini : olmesartan, nebivolol (2017)

- Biotronik : orsiro, magmaris (2017)

- Sanofi Aventis : ramipril, candesartan (2017)

- Bayer : rivaroxabane (2017)

- Astra Zeneca : Ticagrelor, dapagliflozin (2017)


- Merck Sharp & Dohme : bisoprolol (2017)

- Bayer : rivaroxabane (2017)

Tykarski Andrzej 1- Financial Declaration


- Servier : Hyperteension (2017)

- Berlin Menarini : Hypertension (2017)

24/08/2018




51/72

van de Borne Philippe 1- Financial Declaration


- Boehringer-Ingelheim : diabetes (2017)


- Menarini : hypertension (2017)

Vardas Panagiotis 1- Financial Declaration


- European Society of Cardiology : CONSULTING FEES (2017)

- DEAN MEDICUS LTD : CONSULTING FEES (2017)

- Bayer : SPEAKER FEES (2017)

- Boehringer-Ingelheim : SPEAKER FEES (2017)

- MENARINI INTERNATIONAL : SPEAKER FEES (2017)

- AFEA S.A. : SPEAKER FEES (2017)

- Servier : SPEAKER FESS AND CONSULTING FEES (2017)

Vavlukis Marija 1- Financial Declaration


- Jensen, Jensen : investigator (2017)


- Novo-Nordisk : consultancy (2017)

24/08/2018




52/72

Viigimaa Margus 1- Financial Declaration


- Boehringer-Ingelheim : Coagulation (2017)

- Novo-Nordisk : Diabetes (2017)


- Amgen Inc : Lipids (2017)

- Sanofi Aventis : Lipids, hypertension (2017)

Vinereanu Dragos 1- Financial Declaration


- Astra Zeneca : Acute Cororonary Syndromes, Diabetes (2017)

- Boehringer-Ingelheim : Atrial Fibrillation (2017)

- Pfizer : Atrial Fibrillation (2017)

- Novartis : Cardiovascular prevention, Heart Failure (2017)

- Servier : Hypertension, Heart Failure (2017)


- Johnson & Johnson : Clinical trial (2017)

- Quintiles : Clinical trial (2017)

- PPD Global : Clinical trial (2017)

E - Research funding (personal).- Johnson & Johnson : Clinical trial (2017)

- Quintiles : Clinical trial (2017)

- PPD Global : Clinical trial (2017)

24/08/2018




53/72

Vinereanu Dragos - Dalcor : Clinical trial (2017)


2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- Vice-rector of the University; President of the Romanian Society of Cardiology. (2017)

Volpe Massimo 1- Financial Declaration


- Amgen : evolocumab (2017)

- Novartis : LCZ696 (2017)

- Daiichi Sankyo : olmesartan (2017)

- Malesci : olmesartan (2017)

- MENARINI INTERNATIONAL : Olmesartan/amlodipine (Hypertension) (2017)


- Merck Sharp & Dohme : sitagliptin (diabetes), losartan (Hypertension, Heart Failure) (2017)

D - Research funding (departmental or institutional) from healthcare industry.- University "Sapienza" of Rome : Research Award (2017)

Wassmann Sven 1- Financial Declaration


- Amgen : Cardiovascular (2017)


- Boehringer-Ingelheim : Cardiovascular (2017)

- Daiichi Sankyo : Cardiovascular (2017)

- Novartis : Cardiovascular (2017)

24/08/2018




54/72

Wassmann Sven - Pfizer : Cardiovascular (2017)

- Bristol Myers Squibb : Cardiovascular (2017)

- Merck Sharp & Dohme : Cardiovascular (2017)

- Volcano : Cardiovascular (2017)

Weber Thomas 1- Financial Declaration


- Bosch & sons : Blood pressure measurement devices (2017)

- Boehringer-Ingelheim : Diabetes (2017)

- Novartis : Heart Failure, Hypertension (2017)



- Jacobi Pharma : Hypertension (2017)

- Merck Company : Hypertension (2017)

- MSD : Lipidology (2017)

Widimsky Jr Jiri


Windecker Stephan 1- Financial Declaration


- Bayer AG : General Cardiology (2017)

- Abbott : Invasive Cardiology (2017)

- Boston Scientific : Invasive Cardiology (2017)

24/08/2018




55/72

Windecker Stephan - Edwards Lifesciences : invasive Cardiology (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Abbott : General Cardiology (2017)

- Boston Scientific : General Cardiology (2017)

- St. Jude Medical : General Cardiology (2017)

- Amgen Inc. : General Cardiology (2017)

- Symetis SA : Invasive Cardiology (2017)

- Biotronik : Invasive Cardiology (2017)

- Terumo Inc : Invasive Cardiology (2017)


2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- Deputy Editor JACC CV Interventions Section Editor Uptodate Board Member SITEM (Swiss Institute of Translational

and Entreprenieur Medicine) Advisor ECRI (European Cardiovascular Research Institute) Course Director, PCR (2017)

Wittekoek Janneke 1- Financial Declaration


- LEEFH foundation (cascadescreening FH in the Netherlands) : prevention (2017)


- KPN : e-health (2017)

- Amgen : prevention (2017)

- Philips : prevention (2017)

- MSD : prevention (2017)

24/08/2018




56/72

Zamorano Gomez Jose Luis



- Bayer : afib (2017)

- Pfizer : Afib (2017)

Zelveian Parounak 1- Financial Declaration


- Takeda Pharmaceuticals : Hypertension (2017)

- Egis Pharma : Hypertension (2017)

- Grindex : Hypertension (2017)

- Krka Pharma : Hypertension & Atheroclerosis (2017)

24/08/2018




57/72

Aboyans Victor 1- Financial Declaration


- Amgen : Hyperlipidemia (2016-2017)


- Boehringer-Ingelheim : Oral anticoagulation (2016-2017)

- Bayer Healthcare : Oral anticoagulation (2016-2017)

- Pfizer/BMS alliance : Oral anticoagulation (2016-2017)

Agewall Stefan 1- Financial Declaration


- Astra Zeneca : Antiplatelet treatment (2016-2017)

Barbato Emanuele 1- Financial Declaration


- St Jude Medical : Educational courses on FFR (2016)

- Boston Scientific : Education courses on rotational atherectomy (2016-2017)

- Abbott Vascular : Educational courses on FFR (2017)

D - Research funding (departmental or institutional) from healthcare industry.- St Jude Medical : Unrestricted grant for an investigator-driven study (2016-2017)

Bueno Hector 1- Financial Declaration


- Abbott : BVS (2016)

- Servier : ivabradine (2016)

- Novartis : Serelaxin, ACZ885, AHF Academy (2016)

24/08/2018

ESC Committee for Practice Guidelines 2016-2018



58/72

Bueno Hector - Pfizer : Apixaban (2016-2017)

- Bristol Myers Squibb : Apixaban (2016-2017)

- Bayer : Aspirin, rivaroxaban (2016-2017)

- MEDSCAPE-the heart.og : Inespecific (2016-2017)

- Astra Zeneca : Ticagrelor (2016-2017)

- Ferrer Internacional : Trinomia (polypill) (2016-2017)

- Sanofi Aventis : PCSK9 inhibitors (2017)

- Novartis : Serelaxin, ACZ885, AHF Academy, (2017)



E - Research funding (personal).- Novartis : LCZ696 - PROMISE / PERSPECTIVE (2016)

- BMS : CV013-011 - STANDUP-AHF trial (2016-2017)

- Janssen-Cilag : Rivaroxaban - GEMINI ACS Trials 1 & 2 (2016-2017)

- Astra Zeneca : Ticagrelor - EPICOR Study, THEMIS trial (2016-2017)

- Novartis : LCZ696 - PROMISE trial / PERSPECTIVE trial / PREFER Study (2017)


2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.- FAHA (2016)

- VP elect. Spanish Society of Cardiology FAHA (2017)

24/08/2018




59/72



- Boehringer-Ingelheim : Telmisartan; Telmisartan-Amlodipine; Telmisartan-HCTZ (2016)

- Merck Serono : Bisoprolol-Amlodipine (2016-2017)

- Menarini : Nevibolol; Olmesartan; Olmesartan-Amlodipine; Olmesartan-HCTZ (2016-2017)

- Ferrer Internacional : Torasemide; CardioIncode microchips; Polypill (2016-2017)

Collet Jean-Philippe 1- Financial Declaration


- BMS : apixaban (2016)

- Sanofi Aventis : CLOPIDOGREL (2016)

- Medtronic : corevalve (2016)

- Eli Lilly : PRASUGREL (2016)

- Astra-Zeneca : ticagrelor (2016)

- MSD : VORAPAXAR (2016)

- Bayer Healthcare : xarelto (2016)

- Bristol Myers Squibb : Lecture fees representing 2000 euros for 2017. (2017)

- Roche Diagnostics : Lecture fees representing 800 euros for 2017. (2017)

- Bayer Healthcare : Speaker Fees for antiplatelet therapy. This represented 2000 euros in total for 2017. (2017)

- Servier : SPEAKER FEES OF 1000 EUROS IN 2017 (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Bristol Myers Squibb : APIXABAN (2016)

- Medtronic : COREVALVE (2016)

24/08/2018




60/72

Collet Jean-Philippe - Stago : LABORATORY TEST (2016)

- Eli Lilly : PRASUGREL (2016)

- FEDERATION FRANCAISE DE CARDIOLOGIE : THROMBOSIS (2016)

- ICAN : THROMBOSIS (2016)

- Astra Zeneca : TICAGRELOR (2016)

- Boston Scientific : ACADEMIC RESEARCH DONATION TO THE ACTION FOUNDATION (www.action-fonds.org) (2017)

- Bayer AG : ACADEMIC RESEARCH FUNDINGS (ADRIFT TRIALS) to the action study group (www.action-fonds.org) (2017)

- Astra Zeneca : ACADEMIC RESEARCH FUNDINGS (ALPHEUS TRIAL) to the action study group (www.action-fonds.org) (2017)

- Medtronic : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017)

- Bristol Myers Squibb and Pfizer : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017)

Coman Ioan Mircea 1- Financial Declaration


- Daiichi Sankyo : anticoagulants (2016-2017)

- Johnson & Johnson : antithrombotic (2016-2017)

- Bayer AG : antithrombotic (2016-2017)

- Sanofi Aventis : dyslipidemia (2016-2017)

- Fournier Laboratories : dyslipidemia (2016-2017)

- Amgen Inc : dyslipidemia , (2016-2017)

- Novartis : HF (2016-2017)

24/08/2018




61/72

Coman Ioan Mircea - Vifor International : iron deficiency (2016-2017)

- Actelion : PHT (2016-2017)


- Daiichi Sankyo : anticoagulants (2016-2017)

- Johnson & Johnson : antithrombotic (2016-2017)

- Bayer AG : antithrombotic (2016-2017)

- Sanofi Aventis : dyslipidemia (2016-2017)

- Amgen Inc : dyslipidemia (2016-2017)

- Fournier Laboratories : dyslipidemia (2016-2017)

- Novartis : HF (2016-2017)

- Vifor International : iron deficiency (2016-2017)

- Actelion : PHT (2016-2017)

Delgado Victoria 1- Financial Declaration


- Abbott Vascular : Mitraclip (2016-2017)

D - Research funding (departmental or institutional) from healthcare industry.- Boston Scientific : Pacemaker-Heart failure (2016)

- Medtronic : Pacemaker-Heart failure (2016)

- Biotronik : Pacemaker-Heart Failure (2016)

- Edwards Lifesciences : Valvular heart disease (2016)

- Boston Scientific : pacemakers (2017)

- Medtronic : pacemakers (2017)

24/08/2018




62/72

Delgado Victoria - Biotronik : pacemakers (2017)

- Edwards Lifesciences : valves (2017)

Fitzsimons Donna


Gaemperli Oliver 1- Financial Declaration


- GE-Healthcare : Imaging (2016)

- Amgen Inc : PCSK9 (2016)

- Servier : Procorolan (2016)

- GE Healthcare : Imaging (2017)

Hindricks Gerhard 1- Financial Declaration


- Boston Scientific : CIEDs and interventional electrophysiology (2016)

- St Jude Medical : CIEDs and interventional electrophysiology (2016)

- Biotronik : CIEDs and interventional electrophysiology (2016)

- Abbott : Pacemaker, Ablation (2017)

- Biosense Webster : Pacemaker, Ablation (2017)

- Biotronik : Pacemaker, catheter (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Boston Scientific : CIEDs and interventional electrophysiology (2016)

- St Jude Medical : CIEDs and interventional electrophysiology (2016)

- Abbott, Biotronik, Medtronic, Boston Scientific : Electropyhsiology, arrhythmias (2017)

6/1524/08/2018




63/72

Hindricks Gerhard 2- Other Positions of Influence

2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- The Heart Center Leipzig / University Hospital for Cardiology, Cardiac Surgery and Pediatric Cardiology is part of the

Helios Hospital Group. (2017)

Iung Bernard 1- Financial Declaration


- Edwards Lifesciences : Heart Valve Prostheses (2016-2017)

- Boehringer Ingelheim : Anticoagulants (2017)

- Novartis : Heart failure drugs (2017)

Juni Peter



D - Research funding (departmental or institutional) from healthcare industry.- Astra Zeneca : Anti-platelet Therapy (2017)

- Biotronik : Drug-eluting stents (2017)

- Biosensors International Group : Drug-eluting stents (2017)

- The Medicines Company : Thrombin inhibitors (2017)


2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- Peter Jüni has received research grants to the institution from Astra Zeneca, Biotronik, Biosensors International, Eli Lilly

and The Medicines Company, and serves as unpaid member of the steering group of trials funded by Astra Zeneca, Biotronik, Biosensors, St. Jude Medical and The Medicines Company. (2017)

24/08/2018




64/72

Katus Hugo 1- Financial Declaration


- Daiichi Sankyo : Lixiana_NOAK (2016-2017)


- Bayer Vital : Xarelto-NOAK (2016-2017)

D - Research funding (departmental or institutional) from healthcare industry.- St Jude Medical : Biobank (2016-2017)

- Philips : MRT (2016-2017)

Knuuti Juhani 1- Financial Declaration


- Astra Zeneca : Consultancy for a research project for ischemic heart disease (2017)

- GE Healthcare : Consultancy for myocardial perfusion imaging agent (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Orion : Brain diseases (2016)

- AC Immune : Brain diseses (2016)

- Antaros : Endocrinology (2016)

- Boehringer-Ingelheim : Neurology (2016)

- MSD : Neurology (2016)

- GE Gealthcare : Neurology (2016)

Lancellotti Patrizio 1- Financial Declaration


- St Jude Medical : Echo course (2016)

24/08/2018




65/72

Lancellotti Patrizio - Servier : Ischemic Heart Disease (2016-2017)


- Medtronic : Structural disease (2016)

- Bayer : NOAC (2016-2017)

Leclercq Christophe 1- Financial Declaration


- Sorin Group : devices (2016)

- St Jude Medical : devices (2016)

- Bayer Healthcare : DOAC (2016)

- Boston Scientific : devices (2016-2017)

- Medtronic : devices (2016-2017)

- Biotronik : devices (2016-2017)

- Abbott : devices (2017)

- LIvanova : devices (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Biotronik : devices (2017)

McDonagh Theresa 1- Financial Declaration


- Vifor International : Ferrinject (2016-2017)

- Novartis : Honoraria (2016-2017)

- Bayer AG : Honoraria (2017)

24/08/2018




66/72

Piepoli Massimo Francesco




- Servier : Committee member, Speaker fee (2016)

- Novartis : Heart Failure Prevention Initiatives, Advisory Board (2016)

- Amgen : Metabolic, Lipid (2016)


- Novartis : Heart Failure Prevention Initiatives (2016)

Ponikowski Piotr 1- Financial Declaration


- Abbott Vascular : devices (2016)

- BioControl : devices (2016)

- Pfizer : lipids (2016)

- Boehringer-Ingelheim : anticoagulant, diabetes (2016-2017)

- Respicardia : devices (2016-2017)

- Novartis : heart failure (2016-2017)

- Cardiorentis : heart failure (2016-2017)

- Berlin Chemie AG : heart failure (2016-2017)

- Bayer Healthcare : heart failure (2016-2017)

- Vifor Pharma ltd : heart failure (2016-2017)

24/08/2018




67/72

Ponikowski Piotr - CIBIEM : heart failure (2016-2017)

- Servier : heart failure, coronary artery disease (2016-2017)

- Amgen : heart failure, lipids (2016-2017)

- Pfizer : lipids, heart failure (2017)


- DC Device : devices (2016)

- Cardiorentis : heart failure (2016)

- Respicardia : anticoagulant (2016-2017)

- BioControl : devices (2016-2017)

- Novartis : heart failure (2016-2017)

- Bayer Healthcare : heart failure (2016-2017)

- CIBIEM : heart failure (2016-2017)

- Servier : heart failure, coronary artery disease (2016-2017)

- Amgen : heart failure, lipids (2016-2017)

- Cardionomic : devices (2017)

- Impuls Dynamics : devices (2017)

- National Institute of Health : heart failure (2017)

- European Union grant : heart failure, prevention (2017)

Richter Dimitrios 1- Financial Declaration


- Angelini : Lipids (2016)

24/08/2018




68/72

Richter Dimitrios - Swisspharma : lipids-hypertension (2016)

- Astra Zeneca : lipids-thrombosis (2016)

- Pfizer : lipids-thrombosis (2016)

- Winmedica : lipids-thrombosis (2016)

- Boehringer-Ingelheim : thrombosis (2016)

- Menarini : CAD- hypertension (2016-2017)

- Novartis : hypertension (2016-2017)

- Abbott : lipids (2016-2017)

- Amgen : lipids (2016-2017)

- Sanofi Aventis : Lipids (2016-2017)

- Lilly : Lipids (2016-2017)

- Unilever : lipids (2016-2017)

- Merck Sharp & Dohme : lipids (2016-2017)

- Vianex : lipids (2016-2017)

- Galenica : Lipids (2016-2017)

- Teva Pharmaceutical Industries : lipids, hypertension (2016-2017)

- Bayer Healthcare : Thrombosis (2016-2017)

- Edwards Lifesciences : aortic stenosis (2017)


- Unipharma : hypertension-thrombosis (2017)

24/08/2018




69/72

Roffi Marco 1- Financial Declaration


- Terumo Inc : coronary catheters (2016)

- Johnson & Johnson : coronary catheters (2016)

- Astra Zeneca : speaker fees related to the 2015 ESC NSTEMI GL (2016)

D - Research funding (departmental or institutional) from healthcare industry.- Boston Scientific : devices (2016)

- Medtronic : devices (2016)

- Biotronik : devices (2016)

- Terumo Inc : devices (2016)

- Abbott Vascular : devices (2016)

- Boston Scientific : Stents (2017)

- Medtronic : Stents (2017)

- Biotronik : stents (2017)

- Terumo Inc : stents (2017)

- Abbott Vascular : stents (2017)



- Krka Pharma : Arterial Hypertension (2016-2017)

- Novartis : Arterial Hypertension, Heart Failure (2016-2017)

- Merck Sharp & Dohme : Atherosclerosis (2016-2017)

- Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation (2016-2017)

24/08/2018




70/72

Shlyakhto Evgeny - Pfizer : General Cardiology (2016-2017)

Simpson Iain A 2- Other Positions of Influence

2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- Member and Past President of the British Cardiovascular Society Member of the Management Board of the American

College of Cardiology National Cardiovascular Data Registries (2016-2017)

Sousa Uva Miguel




- Boehringer-Ingelheim : Dabigatran (2016)



Windecker Stephan 1- Financial Declaration


- Bayer AG : General Cardiology (2017)

- Abbott : Invasive Cardiology (2017)

- Boston Scientific : Invasive Cardiology (2017)

- Edwards Lifesciences : invasive Cardiology (2017)

D - Research funding (departmental or institutional) from healthcare industry.- St Jude Medical : General Cardiology (2016)

- Terumo Inc : General Cardiology (2016)

- Bracco Pharmaceutical : General Cardiology (2016)

- Boston Scientific : General Cardiology (2016-2017)

24/08/2018




71/72

Windecker Stephan - Abbott : General Cardiology (2017)

- St. Jude Medical : General Cardiology (2017)

- Amgen Inc. : General Cardiology (2017)

- Symetis SA : Invasive Cardiology (2017)

- Biotronik : Invasive Cardiology (2017)

- Terumo Inc : Invasive Cardiology (2017)


2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.- Deputy Editor JACC CV Interventions Section Editor Uptodate Board Member SITEM (Swiss Institute of Translational

and Entreprenieur Medicine) Advisor ECRI (European Cardiovascular Research Institute) Course Director, PCR (2017)

Zamorano Gomez Jose Luis



- Philips : 3D Echocardiography. (2016)

- Servier : Clinical case presentation during ESC Cong 2016 (2016)

- Pfizer : speaker CV risk factors. (2016)

- MSD : speaker. CV risk factors (2016)

- Bayer : afib (2017)

- Pfizer : Afib (2017)

D - Research funding (departmental or institutional) from healthcare industry.- Edwards Lifesciences : Echo for TAVi assessment & Epidemiology of Ao stenosis (2016)

- Abbott : Epidemiology study of Mitral regurgitation (2016)

24/08/2018




72/72

2018 ESC/ESH Guidelines for the management of arterial ...

Documents

Transcript of 2018 ESC/ESH Guidelines for the management of arterial ...